Marij J P Welters

10PUBLICATIONS
80CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMortalityTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 28, 2025
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.

Mitchell Emmers, Marij J P Welters, Michelle V Dietz

|Feb 21, 2024
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.

Xin Lei, Daniël C de Groot, Marij J P Welters

|Jan 09, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.

Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen

|Aug 04, 2023
Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men.

Karien C M Gosens, Sjoerd H van der Burg, Marij J P Welters

|Jul 20, 2023
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.

Markus Haake, Beatrice Haack, Tina Schäfer

|May 08, 2022
T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation.

Janine E Melsen, Monique M van Ostaijen-Ten Dam, Erik B van den Akker

Pageof 2